Cargando…
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
OBJECTIVE: A predictive model for hospitalization due to COVID-19 or death was developed in the placebo group (N=2,084) from a large clinical trial of colchicine in COVID-19 patients (N = 4,159). RESULTS: The 7 variables retained in the predictive model were age, gender, body-mass index, history of...
Autores principales: | Tardif, Jean-Claude, Cossette, Mariève, Guertin, Marie-Claude, Bouabdallaoui, Nadia, Dubé, Marie-Pierre, Boivin, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758567/ https://www.ncbi.nlm.nih.gov/pubmed/35038601 http://dx.doi.org/10.1016/j.ijid.2022.01.020 |
Ejemplares similares
-
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021) -
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
por: Dubé, Marie-Pierre, et al.
Publicado: (2021) -
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Bouabdallaoui, Nadia, et al.
Publicado: (2020) -
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Samuel, Michelle, et al.
Publicado: (2020) -
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
por: Tardif, Jean-Claude, et al.
Publicado: (2021)